Disease · MONDO_0005045
hypertrophic cardiomyopathy
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. hypertrophic cardiomyopathy. Diseases, record MONDO_0005045. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005045
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
Asymmetric Septal Hypertrophies, Asymmetric Septal Hypertrophy, Cardiomyopathies, Hypertrophic, Cardiomyopathies, Hypertrophic Obstructive, Cardiomyopathy, Hypertrophic Obstructive, Cardiomyopathy, hypertrophic, HCM, HCM - Hypertrophic cardiomyopathy, HOCM - Hypertrophic obstructive cardiomyopathy, HYPERTR OBSTR CARDIOMYOP, Hypertrophic Cardiomyopathies, Hypertrophic Obstructive Cardiomyopathies, Hypertrophic Obstructive Cardiomyopathy, Hypertrophic cardiomyopathy (disorder), Hypertrophic obstructive cardiomyopathy (disorder), Hypertrophies, Asymmetric Septal, Hypertrophy, Asymmetric Septal, IDIOPATHIC HYPERTROPHIC SUBVALV STENOSIS, IHSS, IHSSs, Idiopathic Hypertrophic Subaortic Stenosis, Idiopathic Hypertrophic Subvalvular Stenosis, Obstructive Cardiomyopathies, Hypertrophic, Obstructive Cardiomyopathy, Hypertrophic, Obstructive cardiomyopathy, Primary hypertrophic cardiomyopathy, SUBVALV STENOSIS, SUBVALV STENOSIS IDIOPATHIC HYPERTROPHIC, Septal Hypertrophies, Asymmetric, Septal Hypertrophy, Asymmetric, Subvalvular Stenosis, Idiopathic Hypertrophic, hyper. obst. cardiomyopathy, hypertrophic myocardiopathy, hypertrophic subaortic stenosis, obstructive hypertrophic cardiomyopathy, primary hypertrophic cardiomyopathy (disorder) [Ambiguous]
- Open Targets
- Highest stage of its drugs
- Approval, for 2 of its 29 drugs, from EMA Human Drugs, FDA, PMDA and TTD
- Open Targets
Drugs29
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| MAVACAMTEN | CHEMBL4297517 | Small molecule | Approval | EMA Human Drugs, FDA, PMDA and TTD | 37 | 32 | 32 | Drugs and targets |
| AFICAMTEN | CHEMBL4847050 | Small molecule | Approval | EMA Human Drugs | 11 | 8 | 8 | Drugs and targets |
| SOTAGLIFLOZIN | CHEMBL3039507 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ASPIRIN | CHEMBL25 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ATORVASTATIN | CHEMBL1487 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| EMPAGLIFLOZIN | CHEMBL2107830 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| METOPROLOL | CHEMBL13 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PERHEXILINE MALEATE | CHEMBL1334033 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| VALSARTAN | CHEMBL1069 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| SACUBITRIL | CHEMBL3137301 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
1 to 10 of 29
See all 29 drugsTargets24
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| AGTR1 | Type-1 angiotensin II receptor | 3 | Type-1 angiotensin II receptor antagonist | Phase 2/3 | https://conductscience.org/library/genes/185 | Drugs and targets |
| SLC5A2 | Sodium/glucose cotransporter 2 | 3 | Sodium/glucose cotransporter 2 inhibitor | Phase 3 | https://conductscience.org/library/genes/6524 | Drugs and targets |
| ADRB1 | Beta-1 adrenergic receptor | 2 | Beta-1 adrenergic receptor antagonist | Phase 3 | https://conductscience.org/library/genes/153 | Drugs and targets |
| CPT1B | Carnitine O-palmitoyltransferase 1, muscle isoform | 2 | Carnitine O-palmitoyltransferase 1, muscle isoform inhibitor | Phase 3 | https://conductscience.org/library/genes/1375 | Drugs and targets |
| CPT2 | Carnitine O-palmitoyltransferase 2, mitochondrial | 2 | Carnitine palmitoyltransferase 2 inhibitor | Phase 3 | https://conductscience.org/library/genes/1376 | Drugs and targets |
| MAP2K1 | Dual specificity mitogen-activated protein kinase kinase 1 | 2 | Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor | Phase 2 | https://conductscience.org/library/genes/5604 | Drugs and targets |
| MAP2K2 | Dual specificity mitogen-activated protein kinase kinase 2 | 2 | Dual specificity mitogen-activated protein kinase kinase 2 inhibitor; Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor | Phase 2 | https://conductscience.org/library/genes/5605 | Drugs and targets |
| MTOR | Serine/threonine-protein kinase mTOR | 2 | Serine/threonine-protein kinase mTOR inhibitor | Phase 3 | https://conductscience.org/library/genes/2475 | Drugs and targets |
| ACE | Angiotensin-converting enzyme | 1 | Angiotensin-converting enzyme inhibitor | Unknown | https://conductscience.org/library/genes/1636 | Drugs and targets |
| HMGCR | 3-hydroxy-3-methylglutaryl-coenzyme A reductase | 1 | HMG-CoA reductase inhibitor | Phase 3 | https://conductscience.org/library/genes/3156 | Drugs and targets |
1 to 10 of 24
See all 24 targetsTrials73
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05186818 | Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM | Phase 3 | 282 | 2026-03-03 | Obstructive Hypertrophic Cardiomyopathy (oHCM) | AFICAMTEN | Its record names the disease | ClinicalTrials.gov |
| NCT03470545 | Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy | Phase 3 | 251 | 2021-10-04 | Obstructive Hypertrophic Cardiomyopathy | MAVACAMTEN | Its record names the disease | ClinicalTrials.gov |
| NCT02291237 | Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy | Phase 2/3 | 172 | 2018-03-22 | Hypertrophic Cardiomyopathy | ELECLAZINE | Its record names the disease | ClinicalTrials.gov |
| NCT04349072 | A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy | Phase 3 | 112 | 2023-03-07 | HOCM, Hypertrophic Obstructive Cardiomyopathy | MAVACAMTEN | Its record names the disease | ClinicalTrials.gov |
| NCT04219826 | Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Hypertrophic Cardiomyopathy | Phase 2 | 96 | 2026-02-24 | Hypertrophic Cardiomyopathy (HCM) | AFICAMTEN | Its record names the disease | ClinicalTrials.gov |
| NCT05174416 | A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM | Phase 3 | 81 | 2024-09-19 | Obstructive Hypertrophic Cardiomyopathy | MAVACAMTEN | Its record names the disease | ClinicalTrials.gov |
| NCT03442764 | A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) | Phase 2 | 59 | 2022-08-09 | Non-obstructive Hypertrophic Cardiomyopathy | MAVACAMTEN | Its record names the disease | ClinicalTrials.gov |
| NCT04164732 | Study of Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy | Phase 2 | 46 | 2024-08-29 | Cardiomyopathy, Hypertrophic | SACUBITRIL, VALSARTAN | Its record names the disease | ClinicalTrials.gov |
| NCT01537926 | Hypertrophic Regression With N-Acetylcysteine in HCM | Phase 1 | 42 | 2021-11-02 | Hypertrophic Cardiomyopathy | ACETYLCYSTEINE | Its record names the disease | ClinicalTrials.gov |
| NCT05414175 | A Study of Mavacamten in Obstructive Hypertrophic Cardiomyopathy | Phase 3 | 38 | 2024-12-04 | Cardiomyopathy, Hypertrophic Obstructive | MAVACAMTEN | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 73
See all 73 trialsComparisons in its trials30
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Aficamten up to 20 mg vs Placebo to Match Aficamten: Proportion of Participants With ≥1 Class Improvement in NYHA Functional Class From Baseline to Week 12 | 69 of 142 | 25 of 140 | 282 | NCT05186818 | Trial comparisons |
| Aficamten up to 20 mg vs Placebo to Match Aficamten: Proportion of Participants With Valsalva LVOT G <30 mmHg at Week 24 | 70 of 142 | 5 of 140 | 282 | NCT05186818 | Trial comparisons |
| Aficamten up to 20 mg vs Placebo to Match Aficamten: Proportion of Participants With Valsalva LVOT G <30 mmHg at Week 12 | 74 of 142 | 8 of 140 | 282 | NCT05186818 | Trial comparisons |
| Aficamten up to 20 mg vs Placebo to Match Aficamten: Proportion of Participants With ≥1 Class Improvement in New York Heart Association (NYHA) Functional Class From Baseline to Week 24 | 83 of 142 | 34 of 140 | 282 | NCT05186818 | Trial comparisons |
| Aficamten up to 20 mg vs Placebo to Match Aficamten: deaths from any cause | 0 of 142 | 0 of 140 | 282 | NCT05186818 | Trial comparisons |
| Aficamten up to 20 mg vs Placebo to Match Aficamten: serious adverse events | 8 of 142 | 13 of 140 | 282 | NCT05186818 | Trial comparisons |
| Mavacamten (MYK-461) vs Placebo: Proportion of Participants With at Least 1 Class Improvement in NYHA Functional Class From Baseline to Week 30 | 80 of 123 | 40 of 128 | 251 | NCT03470545 | Trial comparisons |
| Mavacamten (MYK-461) vs Placebo: deaths from any cause | 0 of 123 | 1 of 128 | 251 | NCT03470545 | Trial comparisons |
| Mavacamten (MYK-461) vs Placebo: Percentage of Participants Achieving A Clinical Response | 45 of 123 | 22 of 128 | 251 | NCT03470545 | Trial comparisons |
| Mavacamten (MYK-461) vs Placebo: serious adverse events | 14 of 123 | 12 of 128 | 251 | NCT03470545 | Trial comparisons |
1 to 10 of 30
See all 30 comparisons in its trialsPapers from its trials114
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005045
GET https://conductscience.org/api/diseases/v1/MONDO_0005045/drugs?page=2